PET
0.019
171.4%
STP
0.265
-44.2%
CKA
0.073
69.8%
VBS
0.11
-37.1%
A1G
0.52
65.1%
IPB
0.006
-33.3%
APC
0.015
50%
NAE
0.002
-33.3%
AYT
0.006
50%
SFG
0.002
-33.3%
ERA
0.003
50%
OVT
0.005
-28.6%
RMY
0.045
45.2%
VUL
4.41
-27.5%
TCG
0.75
38.9%
IMI
0.011
-26.7%
QFE
0.081
37.3%
CTN
0.003
-25%
PNN
0.12
36.4%
MAY
0.009
-25%
DAL
0.054
35%
RKB
0.003
-25%
DMG
0.008
33.3%
NFM
0.016
-23.8%
FBR
0.004
33.3%
EPI
1.005
-23.3%
MRQ
0.004
33.3%
IBX
0.02
-23.1%
BDG
0.08
29%
RML
0.053
-22.1%
MGA
0.081
28.6%
AUR
0.018
-21.7%
NES
0.009
28.6%
LMG
0.023
-20.7%
GR8
0.205
28.1%
AKN
0.004
-20%
EDU
0.77
27.3%
FCT
0.008
-20%
PKY
0.019
26.7%
GLL
0.008
-20%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella’s (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:

🩸 The current lead product coming out of Arovella Therapeutics’ cell therapy platform – ALA-101 – iNKT cells create receptors that target antigens
🩸 How ALA-101 targets cancers and tumours
🩸 Timing of Phase 1 trials for ALA-101

Watch the full interview ⚡️ https://youtu.be/Hb_HZmKYCNA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697